CTMX · CytomX Therapeutics, Inc.

Summary

CytomX Therapeutics, Inc. reported full year 2025 financial results with revenue of $76.2 million versus $138.1 million in 2024, net loss of $17.4 million, and cash, cash equivalents and investments of $137.1 million as of December 31, 2025, providing runway into Q2 2027. The company announced positive Phase 1 data for Varseta-M in advanced CRC and pipeline updates including FDA alignment plans and upcoming combo trials.